

TRADEMARK ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	ASSIGNS THE ENTIRE INTEREST AND THE GOODWILL		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
LeMaitre Vascular, Inc.		06/30/2011	CORPORATION: DELAWARE
RECEIVING PARTY DATA			
Name:	Duke Vascular, Inc.		
Street Address:	2829 Mission Street		
City:	Santa Cruz		
State/Country:	CALIFORNIA		
Postal Code:	95060		
Entity Type:	CORPORATION: CALIFORNIA		
PROPERTY NUMBERS Total: 3			
Property Type	Number	Word Mark	
Registration Number:	3417879	UNIFIT	
Registration Number:	3883388	TAARGET	
Registration Number:	2629170	ENDOFIT	
CORRESPONDENCE DATA			
Fax Number:	6502842180		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	6502424210		
Email:	kmoore@lbhip.com		
Correspondent Name:	Levine Bagade Han LLP		
Address Line 1:	2400 GENG ROAD		
Address Line 2:	Suite 120		
Address Line 4:	Palo Alto, CALIFORNIA 94303		
ATTORNEY DOCKET NUMBER:	DUKE-X-Z001.00-US		
NAME OF SUBMITTER:	Sanjay S. Bagade		

OP \$90.00 3417879

Signature:	/Sanjay S. Bagade/
Date:	06/05/2012
<p>Total Attachments: 22</p> <p>source=DUKEXZ00100_assignment#page1.tif source=DUKEXZ00100_assignment#page2.tif source=DUKEXZ00100_assignment#page3.tif source=DUKEXZ00100_assignment#page4.tif source=DUKEXZ00100_assignment#page5.tif source=DUKEXZ00100_assignment#page6.tif source=DUKEXZ00100_assignment#page7.tif source=DUKEXZ00100_assignment#page8.tif source=DUKEXZ00100_assignment#page9.tif source=DUKEXZ00100_assignment#page10.tif source=DUKEXZ00100_assignment#page11.tif source=DUKEXZ00100_assignment#page12.tif source=DUKEXZ00100_assignment#page13.tif source=DUKEXZ00100_assignment#page14.tif source=DUKEXZ00100_assignment#page15.tif source=DUKEXZ00100_assignment#page16.tif source=DUKEXZ00100_assignment#page17.tif source=DUKEXZ00100_assignment#page18.tif source=DUKEXZ00100_assignment#page19.tif source=DUKEXZ00100_assignment#page20.tif source=DUKEXZ00100_assignment#page21.tif source=DUKEXZ00100_assignment#page22.tif</p>	

ASSET PURCHASE AGREEMENT

This ASSET PURCHASE AGREEMENT (this "Agreement") is made and entered into as of June 30, 2011 (the "Closing" or "Closing Date") by and among Duke Vascular, Inc., a Delaware corporation, having an office at 2829 Mission St., Santa Cruz, CA 95060 ("Buyer"), and LeMaitre Vascular, Inc, a Delaware corporation, having a principal office at 63 Second Avenue, Burlington, Massachusetts 01803 ("Seller"), and, for the limited purpose of the guarantee set forth on the signature page hereto, Duke Empirical, Inc., a Delaware corporation, having an office at 2829 Mission St., Santa Cruz, CA 95060 ("Duke Empirical").

RECITALS

WHEREAS, Seller owns certain assets, as more particularly described herein, related to the manufacture, marketing and sale of medical devices designed for minimally invasive surgery in the treatment of thoracic and aorto-uni-iliac aneurysms; and

WHEREAS, Seller desires to sell, and Buyer desires to purchase, such assets on the terms and conditions set forth in this Agreement.

NOW, THEREFORE, in consideration of the covenants, promises and representations set forth herein, and for other good and valuable consideration, the parties agree as follows:

ARTICLE I DEFINITIONS

1.1 Certain Definitions. As used herein, the below terms shall have the following meanings:

- (a) "Assets" means those assets of Seller listed below and used exclusively in or pertaining exclusively to the Stent Graft Business:

REDACTED

REDACTED

- (xvi) the patents listed on Exhibit A under the heading Patents (the "Patents");
and
- (xvii) the patents and patent applications listed on Exhibit A under the heading

REDACTED

(d) "Intellectual Property" means all licenses, patents, copyrights, designs and drawings, engineering and manufacturing documents, technical manuals, patterns, processes, formulae, know-how, trade secrets, trademarks, service marks, trade names, domain names, inventions and discoveries (whether patentable or not), computer software, and other similar rights, including without limitation any license or usage rights with respect to any of the foregoing of Seller used exclusively in or pertaining exclusively to the Business (including the Patents), and all applications therefor and registrations thereof, and any and all rights to sue for past, present and future infringement or other violations of the same, and all goodwill associated with any of the foregoing.

REDACTED

**ARTICLE II
PURCHASE AND SALE**

2.1 Purchase and Sale of Assets. Subject to the terms and conditions of this Agreement, Seller does hereby sell, convey, assign and transfer to Buyer, and Buyer hereby purchases, acquires and accepts from Seller at the Closing, all of Seller's right, title and interest in the Assets. All of the Assets shall be sold, conveyed, transferred and assigned to Buyer, and purchased and acquired by Buyer, free and clear of any lien, mortgage, pledge, security interest, judgment, charge or encumbrance of any kind, but otherwise on an "AS IS, WHERE IS" basis, with all faults.

REDACTED

REDACTED

2.5 Assignment and License of Certain Intellectual Property. The parties are executing a Patent Assignment Agreement, in substantially the form of Exhibit F, and a Patent License Agreement, in substantially the form of Exhibit G, in connection herewith, pursuant to which Seller will assign the Patents to Buyer, and Buyer will license back to Seller certain rights under the Patents.

REDACTED

**ARTICLE III
REPRESENTATIONS AND WARRANTIES OF SELLER**

Except as disclosed on Exhibit H, Seller represents and warrants to Buyer as of the date hereof and as of the Closing Date as follows:

3.1 Authority. Except as otherwise specifically set forth herein, Seller has all requisite legal power and authority to enter into this Agreement and to consummate the transactions contemplated hereby. The execution and delivery of this Agreement and the consummation of the transactions contemplated hereby (including the exhibits to the Agreement) have been duly

authorized by all necessary corporate action on the part of Seller, and no further action is required on the part of Seller to authorize this Agreement and the transactions contemplated hereby. This Agreement has been duly executed and delivered by Seller and constitutes the valid and binding obligation of Seller, enforceable against Seller in accordance with its terms, except as such enforceability may be limited by bankruptcy and similar laws and general principles of equity. The execution and delivery of this Agreement by Seller does not, and the consummation of the transactions contemplated hereby (including the exhibits to the Agreement) does not, materially conflict with, or result in any material violation of, or material default under (with or without notice or lapse of time, or both), or give rise to a right of termination, cancellation or acceleration of any obligation or loss of any benefit under any provision of the Certificate of Incorporation or By-Laws of Seller.

3.2 Title. (i) Seller has good and marketable title to the Assets, (ii) Seller has all rights, power and authority to sell, convey, assign, transfer and deliver the Assets to Buyer in accordance with the terms of this Agreement, and (iii) Seller is delivering the Assets to Buyer, free and clear of any lien, mortgage, pledge, security interest, judgment, charge or encumbrance of any kind.

REDACTED

3.4 Trademarks and Other Intellectual Property. There is no written claim, demand, action or governmental investigation, formal or informal, pending which has been actually received by an officer of Seller or is, to Seller's knowledge, threatened, relating to any of the Trademarks, and each Trademark registration exists in good standing. Seller has not received any written notices alleging infringement upon, nor to Seller's knowledge does the manufacture, use and sale of the Products infringe upon any patent, trademark or other intellectual property right of any third person. With respect to the Intellectual Property that is owned by Seller: (i) Seller either possesses all right, title and interest in and to the Intellectual Property, free and clear of any encumbrance, license or other restriction, or otherwise has sufficient rights to use the Intellectual Property pursuant to a license or permission as may be necessary in connection with the operation of the Business; (ii) the Intellectual Property is not subject to any outstanding injunction, judgment, order, decree, ruling or charge; (iii) no action, suit, proceeding, hearing, investigation, charge, complaint, claim or demand is pending or threatened which challenges the legality, validity, enforceability, use or ownership of the Intellectual Property, (iv) Seller has not agreed to indemnify any person for or against any interference, infringement, misappropriation or other conflict with respect to the Intellectual Property; and (v) Seller has not granted any license of any kind in and to such Intellectual Property to any third party; except that (iv) and (v) shall not apply with respect to materials previously provided to Seller in connection with its diligence, including without limitation those contracts set forth on Exhibit A. Each trademark application and registration, other than related to the 'Endofit' mark, and each patent application and issued patent is being diligently prosecuted or is valid and exists in good standing. Seller has never received any claim, demand or notice alleging interference, infringement, misappropriation or violation (including any claim that it must license or refrain from using any such rights of any third party) in the conduct of the Business or its use of the Intellectual Property relating to the

Business. With respect to the Intellectual Property that is the subject of any license, sublicense, agreement or permission: (a) each such license, sublicense, agreement or permission covering the item is legal, valid, binding, enforceable and in full force and effect; (b) neither Seller nor any other party to the license, sublicense, agreement or permission is, in any material respect, in breach or default and no event has occurred which with notice or lapse of time would constitute a breach or default or permit termination, modification or acceleration thereunder; (c) Seller has not received any notice that a party to the license, sublicense, agreement or permission has repudiated any provision thereof; (d) Seller has not received any notice that the underlying Intellectual Property is subject to any outstanding injunction, judgment, order, decree, ruling or charge; (e) Seller has not received any notice that any action, suit, proceeding, hearing, investigation, charge, complaint, claim or demand is pending or is threatened which challenges the legality, validity or enforceability of the underlying Intellectual Property; (f) Seller has not granted any sublicense or similar right with respect to the license, sublicense, agreement or permission, and (g) none of the processes, methodologies, trade secrets, research and development results, and other know-how included in the Intellectual Property, the value of which is contingent upon maintenance of the confidentiality thereof, has been disclosed by Seller to any person other than employees, contractors, customers, representatives and agents of Seller who are parties to customary confidentiality and non-disclosure agreements with Seller or other obligations of confidentiality. Notwithstanding anything contained in this Section 3.4 or any other provision of this Agreement, Seller disclaims all warranties with respect to the Non-Core Patents. Buyer acknowledges that Seller may have failed to maintain or prosecute the Non-Core Patents, and, in some cases, may have actively withdrawn pending applications from consideration.

REDACTED

REDACTED

3.9 Survival. The representations and warranties contained herein shall survive the Closing and shall expire and terminate on the date that is eighteen months following the Closing Date, unless written notice by Buyer of a breach or alleged breach thereof has been provided to Seller on or prior to such date, in which case such representations and warranties, and such indemnification obligations, shall not so expire and terminate; provided, however, that notwithstanding the foregoing or anything else to the contrary herein, the representations set forth in Section 3.2 and any and all indemnification obligations relating thereto, shall not so expire or otherwise terminate on the Termination Date, but shall instead expire on the date which is ninety (90) calendar days following the expiration of the applicable statutes of limitations relating to any claim giving rise to a claim for indemnification by Buyer thereunder.

ARTICLE IV REPRESENTATIONS AND WARRANTIES OF BUYER

Buyer represents and warrants to Seller as of the date hereof and as of the Closing Date as follows:

4.1 Authority. Buyer has all requisite corporate power and authority to enter into this Agreement and to consummate the transactions contemplated hereby, including the assumption of the Clinical Trials. The execution and delivery of this Agreement and the consummation of the transactions contemplated hereby (including the exhibits to the Agreement) have been duly authorized by all necessary corporate action on the part of Buyer and no further action is required on the part of Buyer to authorize the Agreement and the transactions contemplated hereby. This Agreement has been duly executed and delivered by Buyer and constitutes the valid and binding obligation of Buyer, enforceable in accordance with its terms except as such enforceability may be limited by bankruptcy or similar laws and general principles of equity. The execution and delivery of this Agreement by Buyer does not, and the consummation of the transactions contemplated hereby (including the exhibits to the Agreement) do not, materially conflict with, or result in any material violation of, or material default under (with or without notice or lapse of time, or both), or give rise to a right of termination, cancellation or acceleration of any obligation or loss of any benefit under any provision of the Certificate of Incorporation or Bylaws of Buyer.

REDACTED

REDACTED

4.5 Survival. The representations and warranties contained herein shall survive the Closing and shall expire and terminate on the date that is eighteen months following the Closing Date, unless written notice by Seller of a breach or alleged breach thereof has been provided to Buyer on or prior to such date, in which case such representations and warranties, and such indemnification obligations, shall not so expire and terminate; provided, however, that notwithstanding the foregoing or anything else to the contrary herein, the representations set forth in Sections 4.3 and 4.4 and any and all indemnification obligations relating thereto, shall not so expire or otherwise terminate on the Termination Date, but shall instead expire on the date which is ninety (90) calendar days following the expiration of the applicable statutes of limitations relating to any claim giving rise to a claim for indemnification by Seller thereunder..

**ARTICLE V
COVENANTS AND AGREEMENTS**

REDACTED

REDACTED

REDACTED

REDACTED

5.16 Further Assurances; Execution of Further Documents. Each of Seller and Buyer agree that subsequent to the date hereof, upon the written request of the other party, it will promptly execute and deliver or cause to be promptly executed and delivered any further assignment, instruments of transfer, bills of sale or conveyances, and shall otherwise cooperate with the other party, all to the extent reasonably necessary or desirable to confirm the transactions contemplated hereby, and shall further make any filings or correspondence related to the Products with any governmental body, regulatory agency, notified body or other person, including regarding product recalls, adverse event reports and the like, as are reasonably requested by the other party.

**ARTICLE VI
DISCLAIMER**

REDACTED

**ARTICLE VII
INDEMNIFICATION**

REDACTED

REDACTED

**ARTICLE VIII
GENERAL PROVISIONS**

8.1 Notices. All notices and other communications hereunder shall be in writing and shall be deemed given if delivered personally or by commercial delivery service, or mailed by registered or certified mail (return receipt requested) or sent via telecopy (with acknowledgment of complete transmission) to the parties at the following addresses (or at such other address for a party as shall be specified by like notice):

(a) if to Buyer:

Duke Vascular, Inc.
2829 Mission St.
Santa Cruz, CA 95060
Attention: Mr. Rob LaDuca
Telephone / Facsimile: (408) 313-2451 / (831) 420-1196

(b) if to Seller:

LeMaitre Vascular, Inc.
63 Second Avenue
Burlington, MA 01803
Attention: Legal Department
Telephone / Facsimile: 781-221-2266 / 781-425-5049

8.2 Counterparts. This Agreement may be executed in one or more counterparts, all of which shall be considered one and the same agreement and shall become effective when one or more counterparts have been signed by each of the parties and delivered to the other party, it being understood that all parties need not sign the same counterpart. Signatures to this Agreement may be delivered via facsimile or email or other electronic means.

8.3 Entire Agreement. This Agreement, the Patent Assignment and License Agreement, the Trademark Assignment, the exhibits hereto, and the Non-Disclosure Agreement:

(a) constitute the entire agreement among the parties with respect to the subject matter hereof and supersede all prior agreements and understandings, both written and oral, among the parties with respect to the subject matter hereof; (b) are not intended to confer upon any other person any rights or remedies hereunder, unless expressly provided otherwise; and (c) shall not be assigned by operation of law or otherwise except as otherwise specifically provided therein.

8.4 Amendment. This Agreement may be amended by the parties hereto only by execution of an instrument in writing signed on behalf of each of the parties hereto.

8.5 Expenses. All fees and expenses incurred in connection with this Agreement and the transactions contemplated hereby shall be the obligation of the respective party incurring such fees and expenses.

8.6 Severability. In the event that any provision of this Agreement or the application thereof becomes or is declared by a court of competent jurisdiction to be illegal, void or unenforceable, the remainder of this Agreement will continue in full force and effect and the

application of such provision to other persons or circumstances will be interpreted so as to reasonably to effect the intent of the parties hereto. The parties further agree to replace such void or unenforceable provision of this Agreement with a valid and enforceable provision that will achieve, to the extent possible, the economic, business and other purposes of such void or unenforceable provision.

8.7 Other Remedies. Except as otherwise provided herein, any and all remedies herein expressly conferred upon a party will be deemed cumulative with and not exclusive of any other remedy conferred hereby, or by law or equity upon such party, and the exercise by a party of any one remedy will not preclude the exercise of any other remedy.

8.8 Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State of New York, United States of America, without regard to the principles of conflicts of laws thereof.

8.9 Rules of Construction. The parties hereto agree that they have been represented by counsel during the negotiation and execution of this Agreement and, therefore, waive the application of any law, regulation, holding or rule of construction providing that ambiguities in an agreement or other document will be construed against the party drafting such agreement or document.

IN WITNESS WHEREOF, Buyer and Seller have caused this Agreement to be signed by their duly authorized respective officers, all as of the date first written above.

BUYER:

DUKE VASCULAR, INC

By: 

Name: Robert LaDuca

Title: Chief Executive Officer

SELLER:

LEMAITRE VASCULAR, INC.

By: 

Name: David B. Roberts

Title: President

GUARANTEE

Duke Empirical, Inc. hereby guarantees the performance of those obligations of Buyer set forth in Articles II and VII of this Agreement, and further represents and warrants to Buyer the accuracy of Seller's representations and warranties set forth in Section 4.3.

DUKE EMPIRICAL, INC

By: 

Name: Robert LaDuca

Title: Chief Executive Officer

Assets



REDACTED

REDACTED

Trademarks

<i>MARK</i>	<i>COUNTRY</i>	<i>REGISTRATION NUMBER</i>	<i>APPLICATION NUMBER</i>
UniFit	United States	3417879	
UniFit	Community Trademark for European Union	007491574	
UniFit	China		6632602
TAArget	United States	3883388	
TAArget	Community Trademark for European Union	007498843	
TAArget	Pending in China		7213277
EndoFit	United States	2629170	
EndoFit*	Community Trademark for European Union	002212546	
EndoFit	Canada	TMA612954	
EndoFit	Japan		41941/2001

*May have lapsed. Renewal date was May 11, 2011.

REDACTED

Patents

- U.S. #6,402,779
- U.S. #6,443,981
- Germany DE60123807

REDACTED

REDACTED

Non-Core Patents

Description	Country	Patent #	Grant Date	Application #	Filing Date	International App. #
Intraluminal Stent Graft	DE	EP 1 202 682 B1	12-Jan-2005	952172.5	24-Jul-2000	PCT/US2000/020095
Expandable Endovascular Graft and Method for Deploying the Same	EP	EP 0 766 539 B1	21-May-2003	95921622.7	7-Jun-1995	PCT/US1995/007258
Method of Making Large Diameter Vascular Prostheses and a Vascular Prosthesis Made by Said Method	EP	EP 1 148 838 B1	17-Aug-2005	905862.7	1-Feb-2000	PCT/US2000/02459
Intraluminal Stent Graft	EP	EP 1 202 682 B1	12-Jan-2005	952172.5	24-Jul-2000	PCT/US2000/020095
Method of Manufacturing Custom Intravascular Devices	EP	EP 1 311 210 B1	11-Oct-2006	1866090.1	23-Aug-2001	PCT/US2001/026250
Curable Fiber Composite Stent and Delivery System	EP	EP 0 836 448	23-Apr-2003	96918086.8	5-Jun-1996	PCT/US1996/008891
Intraluminal Stent Graft	ES	EP 1 202 682 B1	12-Jan-2005	952172.5	24-Jul-2000	PCT/US2000/020095
Intraluminal Stent Graft	FR	EP 1 202 682 B1	12-Jan-2005	952172.5	24-Jul-2000	PCT/US2000/020095
Intraluminal Stent Graft	GB	EP 1 202 682 B1	12-Jan-2005	952172.5	24-Jul-2000	PCT/US2000/020095
Expandable Endovascular Graft and Method for Deploying the Same	GR	EP 0 766 539 B1	21-May-2003	95921622.7	7-Jun-1995	PCT/US1995/007258
Expandable Endovascular Graft and Method for Deploying the Same	GR	EP 0 766 539 B1	21-May-2003	95921622.7	7-Jun-1995	PCT/US1995/007258
Method of Manufacturing Custom Intravascular Devices	IE	1311210	11-Oct-2006	1966090.1	23-Aug-2001	PCT/US2001/026250
Intraluminal Stent Graft	IT	EP 1 202 682 B1	12-Jan-2005	952172.5	24-Jul-2000	PCT/US2000/020095
Bifurcated Stent Graft and Apparatus for Making Same	US			10/865,486	8-Jun-2004	
Catheter for Release of Stent Graft	US			10/971,783	22-Oct-2004	
Bifurcated Stent Graft and Apparatus for Making Same	WO			PCT/US2005/ 020340	8-Jun-2005	PCT/US2005/020340
Delivery System for Self-Expanding Stents and Grafts	WO			PCT/US2000/ 025969	22-Sep-2000	PCT/US2000/025969
Expandable Endovascular Graft and Method for Deploying the same	WO			PCT/US1995/ 007258	7-Jun-1995	PCT/US1995/007258
Intraluminal Stent Graft	WO			PCT/US2000/ 020095	24-Jul-2000	PCT/US2000/020095

Method of Making Large Diameter Vascular Prostheses and a Vascular Prosthesis Made by Said Method	WO			PCT/US2000/002459	1-Feb-2000	PCT/US2000/002459
	WO			PCT/US2005/020340	8-Jun-2005	PCT/US2005/020340
Method of Manufacturing Custom Intravascular Devices	WO			PCT/US2001/026250	23-Aug-2001	PCT/US2001/026250
A Balloon-Assisted Intraluminal Stent Graft	EP	-	-	5000407.6	24-Jul-2000	
Method of Manufacturing Custom Intravascular Devices	EP			6021208.1	23-Aug-2001	
Expandable Endovascular Graft and Method for Deploying the Same	DE	EP 0 766 539 B1	21-May-2003	95921622.7	7-Jun-1995	PCT/US1995/007258
Method of Making Large Diameter Vascular Prostheses and a Vascular Prosthesis Made by Said Method	JP	-	-	2000-596863	29-Oct-2002	
A Balloon-Assisted Intraluminal Stent Graft	JP	-	-	2001-511846	24-Jul-2000	
Expandable Endovascular Graft and Method for Deploying the Same	JP	3,662,256	1-Apr-2005	502326/96		PCT/US1995/007258
Expandable Endovascular Graft and Method for Deploying the Same	IT	EP 0 766 539 B1	21-May-2003	95921622.7	7-Jun-1995	PCT/US1995/007258
Method of Manufacturing Custom Intravascular Devices	JP	-	-	2002-520738	24-Feb-2003	PCT/US2001/026250
Expandable Endovascular Graft and Method for Deploying the Same	FR	EP 0 766 539 B1	21-May-2003	95921622.7	7-Jun-1995	PCT/US1995/007258
Expandable Endovascular Graft and Method for Deploying the Same	ES	EP 0 766 539 B1	21-May-2003	95921622.7	7-Jun-1995	PCT/US1995/007258
Expandable Endovascular Graft and Method for Deploying the Same	GB	EP 0 766 539 B1	21-May-2003	95921622.7	7-Jun-1995	PCT/US1995/007258
Method of Making Large Diameter Vascular Prostheses and a Vascular Prosthesis Made by Said Method	IT	EP 1 148 838 B1	17-Aug-2005	905882.7	1-Feb-2000	PCT/US2000/02459
Method of Making Large Diameter Vascular Prostheses and a Vascular Prosthesis Made by Said Method	FR	EP 1 148 838 B1	17-Aug-2005	905882.7	1-Feb-2000	PCT/US2000/02459

Method of Making Large Diameter Vascular Prostheses and a Vascular Prosthesis Made by Said Method	ES	EP 1 148 838 B1	17-Aug-2005	905882.7	1-Feb-2000	PCT/US2000/02459
Method of Making Large Diameter Vascular Prostheses and a Vascular Prosthesis Made by Said Method	GB	EP 1 148 838 B1	17-Aug-2005	905882.7	1-Feb-2000	PCT/US2000/02459
Method of Manufacturing Custom Intravascular Devices	IT	EP 1 311 210 B1	11-Oct-2006	1966090.1	23-Aug-2001	PCT/US2001/026250
Method of Manufacturing Custom Intravascular Devices	ES	2274902	11-Oct-2006	1966090.1	23-Aug-2001	PCT/US2001/026250
Method of Manufacturing Custom Intravascular Devices	GB	EP 1 311 210 B1	11-Oct-2006	1966090.1	23-Aug-2001	PCT/US2001/026250
Method of Manufacturing Custom Intravascular Devices	FR	EP 1 311 210 B1	11-Oct-2006	1966090.1	23-Aug-2001	PCT/US2001/026250
A Method of Making Large Diameter Vascular Prostheses and a Vascular Prosthesis Made by Said Method	CA	-	-	2,361,063	1-Feb-2000	PCT/US2000/002459
Intraluminal Stent Graft	CA	-	-	2,378,360	24-Jul-2000	PCT/US2000/020095
Method of Manufacturing Custom Intravascular Devices	CA	-	-	2,421,060	23-Aug-2001	PCT/US2001/026250
Expandable Endovascular Graft and Method for Deploying the Same	CA	2,192,974	10-Oct-2006	2,192,974	7-Jun-1995	PCT/US1995/007268
Delivery System for Self-Expanding Stents and Grafts	US	6,183,481	6-Feb-2001	09/401,599	22-Sep-1999	
Multiple Diameter Expandable Graft for Blood Vessel and Method for Deploying the Same	US	6,098,830	8-Aug-2000	09/885,626	30-Jun-1997	
Method of Making Large Diameter Vascular Prostheses and Vascular Prosthesis Made by Said Method	US	6,187,054	13-Feb-2001	09/244,343	4-Feb-1999	
Method of Making Large Diameter Vascular Prostheses and a Vascular Prosthesis Made by Said Method	DE	EP 1 148 838 B1	17-Aug-2005	905882.7	1-Feb-2000	PCT/US2000/02459
Method of Making Large Diameter Vascular Prostheses and Vascular Prosthesis Made by Said Method	US	6,605,119	12-Aug-2003	09/703,565	1-Nov-2000	
Method of Manufacturing Custom Intravascular Devices	US	-	-	09/644,640	23-Aug-2000	PCT/US2001/026250

Method of Manufacturing Custom Intravascular Devices	ES		11-Oct-2006	1966090.1	23-Aug-2001	PCT/US2001/026250
Expandable Intra-luminal Vascular Graft	US	5,123,917	23-Jun-1992	07/516,104	27-Apr-1990	